Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPLE-2: Osimertinib in EGFR mutant NSCLC
NCT05785208Phase 4Unknown
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05785208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05785208.